Raia DrogasilBSP:RADL3 +3.53%91 Buyback Yield % is 0.02 as of Jul. 12, 2026, which is 89% below its 10-year median of 0.19. GuruFocus rates BSP:RADL3 with a GF Score™ of 91/100 and a GF Value™ of R$29.99 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 274 Healthcare Providers & Services companies, Raia Drogasil ranks better than 56.93% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Raia Drogasil's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Raia Drogasil's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raia Drogasil (BSP:RADL3) has a Buyback Yield % of 0.02 as of Jul. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Raia Drogasil and its competitors. This is 89% below median its historical median of 0.19. Over the past decade, Raia Drogasil's Buyback Yield % has ranged from 0.01 to 0.25. According to the industry distribution chart, Raia Drogasil ranks #118 out of 274 companies in the Healthcare Providers & Services industry, placing it in the top 43.1%.
Is Raia Drogasil's Buyback Yield % too high?
Raia Drogasil's current Buyback Yield % of 0.02 is 89% below median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.25. Based on the distribution chart, Raia Drogasil ranks #118 out of 274 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Raia Drogasil has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's Buyback Yield % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #118 out of 274 companies for Buyback Yield %. This puts Raia Drogasil in the upper half of its industry. Historically, Raia Drogasil's own Buyback Yield % has ranged from 0.01 to 0.25 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Raia Drogasil and its competitors. Raia Drogasil's current Buyback Yield % is 0.02, which is 89% below median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Significantly Undervalued. The stock's GF Value™ is R$29.99, compared to a current price of R$18.77 — trading 37.4% below its estimated fair value. The current Buyback Yield % is 0.02, which is 89% below median its 10-year median of 0.19. Raia Drogasil's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current Buyback Yield % is 0.02 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$18.77 is trading 37.4% below its estimated GF Value™ of R$29.99.
GuruFocus considers Raia Drogasil to be Significantly Undervalued.
Key valuation signals for BSP:RADL3:
Buyback Yield %: 0.02 (89% below median its 10-year median of 0.19)
GF Value™: R$29.99 vs. price of R$18.77 (37.4% below fair value)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
91GF Score
Get the complete analysis for BSP:RADL3
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
